摘要
目的探讨miR-409-3p和miR-325-3p与原发性肝癌患者介入治疗疗效的关系。方法选取2021年10月至2024年1月在南阳市中心医院就诊的96例原发性肝癌患者作为肝癌组,患者均行经导管肝动脉化疗栓塞术(TACE),根据治疗效果分为有效组(完全缓解、部分缓解)和无效组(疾病稳定、疾病进展),并选取同期在南阳市中心医院进行治疗的91例肝硬化患者作为肝硬化组,同期在本院进行体检的98名健康者作为对照组。检测血清miR-409-3p、miR-325-3p水平,并分析二者相关性;Logistic回归分析影响原发性肝癌患者TACE治疗疗效的相关因素;进一步通过ROC曲线评估血清miR-409-3p、miR-325-3p水平以及二者联合对原发性肝癌TACE治疗疗效预测价值。结果与对照组相比,肝硬化组和肝癌组血清miR-409-3p、miR-325-3p水平均降低(P<0.05);与肝硬化组相比,肝癌组血清miR-409-3p、miR-325-3p水平均降低(P<0.05)。与有效组相比,无效组血清miR-409-3p、miR-325-3p水平均显著降低(P<0.05)。原发性肝癌患者血清miR-409-3p水平与miR-325-3p水平存在明显的正相关关系(r=0.472,P<0.001)。miR-409-3p、miR-325-3p水平升高是原发性肝癌患者TACE治疗后无效的保护因素(P<0.05)。血清miR-409-3p、miR-325-3p二者联合预测原发性肝癌患者TACE治疗后无效优于单独预测(Z二者联合-miR-409-3p=4.556,P<0.001、Z二者联合-miR-325-3p=2.613,P<0.01)。结论在原发性肝癌患者中血清miR-409-3p、miR-325-3p水平降低,且与介入治疗疗效有关。
Objective To explore the relationship between miR-409-3p and miR-325-3p with the efficacy of interventional therapy in patients with primary liver cancer.Methods Ninety-six patients with primary liver cancer who visited Nanyang Central Hospital from October 2021 to January 2024 were regarded as the liver cancer group.All patients underwent transcatheter arterial chemoembolization(TACE)treatment and were separated into an effective group(complete remission,partial remission)and an ineffective group(disease stability,disease progression)based on the treatment effect.Totally 91 patients with liver cirrhosis who underwent treatment in our hospital during the same period were selected as liver cancer group and 98 healthy individuals who received physical examinations during the same period were selected as the healthy group.Serum miR-409-3p,miR-325-3p levels were detected and analyzed for their correlation.Logistic regression was applied to analyze the relevant factors affecting the efficacy of TACE treatment.Receiver operating characteristic(ROC)curve was applied to evaluate their predictive value for TACE treatment efficacy of serum miR-409-3p,miR-325-3p levels.Results Compared with the healthy group,the serum level of miR-409-3p and miR-325-3p in the liver cirrhosis group and liver cancer group were reduced(P<0.05).Compared with the liver cirrhosis group,the serum level of miR-409-3p and miR-325-3p in the liver cancer group were also reduced(P<0.05).Compared with the effective group,the serum level of miR-409-3p and miR-325-3p in the ineffective group significantly decreased(P<0.05).There was a positive correlation between serum level of miR-409-3p and of miR-325-3p in patients with primary liver cancer(r=0.472,P<0.001).The elevated level of miR-409-3p and miR-325-3p were protective factors for ineffective TACE treatment in primary liver cancer patients(P<0.05).The combination of serum miR-409-3p and miR-325-3p was superior to single prediction in predicting efficacy after TACE treatment in primary liver cancer patients(Z combination-miR-409-3p=4.556,P<0.001,Z combination-miR-325-3p=2.613,P<0.01).Conclusions The serum level of miR-409-3p as well as miR-325-3p is both reduced in patients with primary liver cancer,and is related to the efficacy of interventional therapy.
作者
贾会文
刘赟
徐赟
杨启
杨科
JIA Huiwen;LIU Yun;XU Yun;YANG Qi;YANG Ke(Department of General Surgery,Nanyang Central Hospital,Nanyang 473000,China)
出处
《基础医学与临床》
2025年第3期341-345,共5页
Basic and Clinical Medicine
基金
2024年度河南医学科学项目(2024-YJ-169)。
